Abstract
Kinase Therapeutics: A Wealth of Targets Sparks a Highly Active Market reviews
the considerable array of drug development efforts directed at kinases. This
new CHA Advances report describes the various classes of kinases for which
inhibitors are being developed, and examines the general strategies and
technologies being employed to commercialize kinase inhibitors, including
those underway at major pharmaceutical companies.
The ubiquity of kinases as potential targets means that eventually they will
be exploited for virtually every human disease, particularly diabetes,
inflammatory disorders, and especially cancer. The success of Novartis'
Gleevec and Roche's Herceptin has demonstrated that kinase inhibitors for
cancer that are effective and well-tolerated can enjoy strong sales.
Kinase modulation is without doubt a novel and promising approach to treating
disease, but challenges remain. Those evaluated in the report include:
- Ensuring target relevance and specificity.
- Overcoming resistance.
- Designing clinical trials to maximize the response to a drug.
- Addressing the high cost of novel therapeutics.
Kinase Therapeutics: A Wealth of Targets Sparks a Highly Active Market
evaluates the market potential for kinase-targeting compounds in development
for a variety of diseases. Only those conditions for which drug candidates
have reached at least mid-stage clinical development are covered. The report
addresses the major disease categories, including:
- Patient numbers for diseases of interest to developers of kinase
modulators.
- Competing therapeutics already on the market, particularly those that have
recently gained regulatory approval.
- Evaluation of the pros and cons of various targets and therapeutic
approaches
- Estimates of market sizes in dollars, where available.
Kinases represent perhaps the largest druggable class of targets. And yet
researchers have only started to scratch the surface. Most, if not all, big
pharmas have programs in this area, and are in fact among the leaders in the
field. This report is crucial reading for executives who need to stay on top
of the technical and commercial developments in the area of kinase
therapeutics.
About the Author
Mark C. Via, an editor at CTB International Publishing, has ten years'
experience writing and editing for pharmaceutical trade publications. Mr. Via
holds a B.A. degree in history from Williams College. Mr. Via has authored
previous Advances reports, including Inflammatory Disease Therapeutics:
Pipelines and Competitive Dynamics.
| 
View Cart
